Benitec Biopharma Inc.
BNTCHealthcare|Biotechnology|US
$9.54
+0.90 (+10.42%)
DCF Value
$2.63
Tangible Book / Share
$3.80
Cash / Share
$3.87
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06185673 A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia | Oculopharyngeal Muscular Dystrophy | P1P2 | Recruiting | 30 | Open-label | — |
| NCT03433027 A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | P2 | Completed | 16 | Open-label | BB-401 |